Within-season influenza vaccine waning suggests potential net benefits to delayed vaccination in older adults in the United States
There is growing evidence that there is within (intra-) season waning of influenza vaccine protection in older adults, suggesting there may be a benefit to giving influenza vaccine closer to the time of increased infection risk. We aimed to quantitatively evaluate the impact of modifying the timing...
Gespeichert in:
Veröffentlicht in: | Vaccine 2018-09, Vol.36 (39), p.5910-5915 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 5915 |
---|---|
container_issue | 39 |
container_start_page | 5910 |
container_title | Vaccine |
container_volume | 36 |
creator | Newall, A.T. Chen, C. Wood, J.G. Stockwell, M.S. |
description | There is growing evidence that there is within (intra-) season waning of influenza vaccine protection in older adults, suggesting there may be a benefit to giving influenza vaccine closer to the time of increased infection risk. We aimed to quantitatively evaluate the impact of modifying the timing of influenza vaccination in U.S. older adults.
Using historical data (2010/2011–2015/2016, inclusive) on influenza activity and vaccine uptake, we explore the optimal time to begin vaccinating older adults (≥65 years) in the U.S. to maximize prevention of influenza. We modelled the effect of changing the timing of vaccination by estimating the percentage change to the current disease burden and used this to calculate the estimated optimal week to begin vaccination in the U.S.
When we assumed a relatively slower waning protection rate (over 52 weeks), the estimated optimal time to begin vaccinating those aged ≥65 years varied between mid-August (week 34, 2012–2013) and mid-late October (week 43, 2011–2012) depending on the season, resulting in 0.44% and 5.11% of the current disease burden prevented respectively. Under faster waning (over 26 weeks), the estimated optimal week varied between early September (week 37, 2012–2013) and mid-November (week 47, 2011–2012), resulting in 3.69% and 11.97% of the current disease burden prevented respectively.
While it is difficult to determine the ideal time to start to vaccinate due to substantial variation in timing of individual seasons, we found that there are potentially substantial benefits to minimizing the time between vaccination and influenza activity in U.S. older adults. Modest delays in immunization were beneficial in the seasons we evaluated. If further evidence suggests fast waning, longer delays may be warrant as in these scenarios the timing of the current vaccination was often very suboptimal. |
doi_str_mv | 10.1016/j.vaccine.2018.08.007 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2094427414</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X18311149</els_id><sourcerecordid>2100343624</sourcerecordid><originalsourceid>FETCH-LOGICAL-c445t-9872b63268fd276b825b2bf29d2e6ef7f0dd39e736775611e31048cb94adfb5b3</originalsourceid><addsrcrecordid>eNqFkU9v1DAQxS0EokvhI4AsceGSZfwndnJCqKKAVIkDrcrNsuPJ1quss8ROUTn2k9fLBg69II1kefR7z555hLxmsGbA1Pvt-tZ2XYi45sCaNZQC_YSsWKNFxWvWPCUr4EpWksGPE_IipS0A1IK1z8mJACaVBLEi99ch34RYJbRpjDTEfpgx_rZ0cae_bAxxQ9O82WDKie7HjDEHO9CImTqM2IfSziP1ONg79IvS5vDHj46Dx4laPw8FK_d8g_QqhlzI79lmTC_Js94OCV8t5ym5Ov90efaluvj2-evZx4uqk7LOVdto7pTgquk918o1vHbc9bz1HBX2ugfvRYtaKK1rxRgKBrLpXCut713txCl5d_TdT-PPuQxjdiF1OAw24jgnw6GVkmvJZEHfPkK34zzF8jvDGYCQQvEDVR-pbhpTmrA3-yns7HRnGJhDSGZrljWaQ0gGSoEuujeL--x26P-p_qZSgA9HAMs6bgNOJnUBY4c-TNhl48fwnyceAJQVpx0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2100343624</pqid></control><display><type>article</type><title>Within-season influenza vaccine waning suggests potential net benefits to delayed vaccination in older adults in the United States</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>ProQuest Central UK/Ireland</source><creator>Newall, A.T. ; Chen, C. ; Wood, J.G. ; Stockwell, M.S.</creator><creatorcontrib>Newall, A.T. ; Chen, C. ; Wood, J.G. ; Stockwell, M.S.</creatorcontrib><description>There is growing evidence that there is within (intra-) season waning of influenza vaccine protection in older adults, suggesting there may be a benefit to giving influenza vaccine closer to the time of increased infection risk. We aimed to quantitatively evaluate the impact of modifying the timing of influenza vaccination in U.S. older adults.
Using historical data (2010/2011–2015/2016, inclusive) on influenza activity and vaccine uptake, we explore the optimal time to begin vaccinating older adults (≥65 years) in the U.S. to maximize prevention of influenza. We modelled the effect of changing the timing of vaccination by estimating the percentage change to the current disease burden and used this to calculate the estimated optimal week to begin vaccination in the U.S.
When we assumed a relatively slower waning protection rate (over 52 weeks), the estimated optimal time to begin vaccinating those aged ≥65 years varied between mid-August (week 34, 2012–2013) and mid-late October (week 43, 2011–2012) depending on the season, resulting in 0.44% and 5.11% of the current disease burden prevented respectively. Under faster waning (over 26 weeks), the estimated optimal week varied between early September (week 37, 2012–2013) and mid-November (week 47, 2011–2012), resulting in 3.69% and 11.97% of the current disease burden prevented respectively.
While it is difficult to determine the ideal time to start to vaccinate due to substantial variation in timing of individual seasons, we found that there are potentially substantial benefits to minimizing the time between vaccination and influenza activity in U.S. older adults. Modest delays in immunization were beneficial in the seasons we evaluated. If further evidence suggests fast waning, longer delays may be warrant as in these scenarios the timing of the current vaccination was often very suboptimal.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2018.08.007</identifier><identifier>PMID: 30146403</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Adults ; Age Factors ; Aged ; Aged, 80 and over ; Elderly ; Female ; Health risks ; Humans ; Immunization ; Immunization Schedule ; Influenza ; Influenza Vaccines - administration & dosage ; Influenza, Human - epidemiology ; Influenza, Human - prevention & control ; Intraseason ; Laboratories ; Male ; Models, Theoretical ; Older people ; Population ; Seasons ; Timing ; United States - epidemiology ; Vaccination ; Vaccination - methods ; Vaccination Coverage ; Vaccines ; Waning</subject><ispartof>Vaccine, 2018-09, Vol.36 (39), p.5910-5915</ispartof><rights>2018 Elsevier Ltd</rights><rights>Copyright © 2018 Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited Sep 18, 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c445t-9872b63268fd276b825b2bf29d2e6ef7f0dd39e736775611e31048cb94adfb5b3</citedby><cites>FETCH-LOGICAL-c445t-9872b63268fd276b825b2bf29d2e6ef7f0dd39e736775611e31048cb94adfb5b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2100343624?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3548,27922,27923,45993,64383,64385,64387,72239</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30146403$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Newall, A.T.</creatorcontrib><creatorcontrib>Chen, C.</creatorcontrib><creatorcontrib>Wood, J.G.</creatorcontrib><creatorcontrib>Stockwell, M.S.</creatorcontrib><title>Within-season influenza vaccine waning suggests potential net benefits to delayed vaccination in older adults in the United States</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>There is growing evidence that there is within (intra-) season waning of influenza vaccine protection in older adults, suggesting there may be a benefit to giving influenza vaccine closer to the time of increased infection risk. We aimed to quantitatively evaluate the impact of modifying the timing of influenza vaccination in U.S. older adults.
Using historical data (2010/2011–2015/2016, inclusive) on influenza activity and vaccine uptake, we explore the optimal time to begin vaccinating older adults (≥65 years) in the U.S. to maximize prevention of influenza. We modelled the effect of changing the timing of vaccination by estimating the percentage change to the current disease burden and used this to calculate the estimated optimal week to begin vaccination in the U.S.
When we assumed a relatively slower waning protection rate (over 52 weeks), the estimated optimal time to begin vaccinating those aged ≥65 years varied between mid-August (week 34, 2012–2013) and mid-late October (week 43, 2011–2012) depending on the season, resulting in 0.44% and 5.11% of the current disease burden prevented respectively. Under faster waning (over 26 weeks), the estimated optimal week varied between early September (week 37, 2012–2013) and mid-November (week 47, 2011–2012), resulting in 3.69% and 11.97% of the current disease burden prevented respectively.
While it is difficult to determine the ideal time to start to vaccinate due to substantial variation in timing of individual seasons, we found that there are potentially substantial benefits to minimizing the time between vaccination and influenza activity in U.S. older adults. Modest delays in immunization were beneficial in the seasons we evaluated. If further evidence suggests fast waning, longer delays may be warrant as in these scenarios the timing of the current vaccination was often very suboptimal.</description><subject>Adults</subject><subject>Age Factors</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Elderly</subject><subject>Female</subject><subject>Health risks</subject><subject>Humans</subject><subject>Immunization</subject><subject>Immunization Schedule</subject><subject>Influenza</subject><subject>Influenza Vaccines - administration & dosage</subject><subject>Influenza, Human - epidemiology</subject><subject>Influenza, Human - prevention & control</subject><subject>Intraseason</subject><subject>Laboratories</subject><subject>Male</subject><subject>Models, Theoretical</subject><subject>Older people</subject><subject>Population</subject><subject>Seasons</subject><subject>Timing</subject><subject>United States - epidemiology</subject><subject>Vaccination</subject><subject>Vaccination - methods</subject><subject>Vaccination Coverage</subject><subject>Vaccines</subject><subject>Waning</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkU9v1DAQxS0EokvhI4AsceGSZfwndnJCqKKAVIkDrcrNsuPJ1quss8ROUTn2k9fLBg69II1kefR7z555hLxmsGbA1Pvt-tZ2XYi45sCaNZQC_YSsWKNFxWvWPCUr4EpWksGPE_IipS0A1IK1z8mJACaVBLEi99ch34RYJbRpjDTEfpgx_rZ0cae_bAxxQ9O82WDKie7HjDEHO9CImTqM2IfSziP1ONg79IvS5vDHj46Dx4laPw8FK_d8g_QqhlzI79lmTC_Js94OCV8t5ym5Ov90efaluvj2-evZx4uqk7LOVdto7pTgquk918o1vHbc9bz1HBX2ugfvRYtaKK1rxRgKBrLpXCut713txCl5d_TdT-PPuQxjdiF1OAw24jgnw6GVkmvJZEHfPkK34zzF8jvDGYCQQvEDVR-pbhpTmrA3-yns7HRnGJhDSGZrljWaQ0gGSoEuujeL--x26P-p_qZSgA9HAMs6bgNOJnUBY4c-TNhl48fwnyceAJQVpx0</recordid><startdate>20180918</startdate><enddate>20180918</enddate><creator>Newall, A.T.</creator><creator>Chen, C.</creator><creator>Wood, J.G.</creator><creator>Stockwell, M.S.</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20180918</creationdate><title>Within-season influenza vaccine waning suggests potential net benefits to delayed vaccination in older adults in the United States</title><author>Newall, A.T. ; Chen, C. ; Wood, J.G. ; Stockwell, M.S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c445t-9872b63268fd276b825b2bf29d2e6ef7f0dd39e736775611e31048cb94adfb5b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adults</topic><topic>Age Factors</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Elderly</topic><topic>Female</topic><topic>Health risks</topic><topic>Humans</topic><topic>Immunization</topic><topic>Immunization Schedule</topic><topic>Influenza</topic><topic>Influenza Vaccines - administration & dosage</topic><topic>Influenza, Human - epidemiology</topic><topic>Influenza, Human - prevention & control</topic><topic>Intraseason</topic><topic>Laboratories</topic><topic>Male</topic><topic>Models, Theoretical</topic><topic>Older people</topic><topic>Population</topic><topic>Seasons</topic><topic>Timing</topic><topic>United States - epidemiology</topic><topic>Vaccination</topic><topic>Vaccination - methods</topic><topic>Vaccination Coverage</topic><topic>Vaccines</topic><topic>Waning</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Newall, A.T.</creatorcontrib><creatorcontrib>Chen, C.</creatorcontrib><creatorcontrib>Wood, J.G.</creatorcontrib><creatorcontrib>Stockwell, M.S.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Newall, A.T.</au><au>Chen, C.</au><au>Wood, J.G.</au><au>Stockwell, M.S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Within-season influenza vaccine waning suggests potential net benefits to delayed vaccination in older adults in the United States</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2018-09-18</date><risdate>2018</risdate><volume>36</volume><issue>39</issue><spage>5910</spage><epage>5915</epage><pages>5910-5915</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>There is growing evidence that there is within (intra-) season waning of influenza vaccine protection in older adults, suggesting there may be a benefit to giving influenza vaccine closer to the time of increased infection risk. We aimed to quantitatively evaluate the impact of modifying the timing of influenza vaccination in U.S. older adults.
Using historical data (2010/2011–2015/2016, inclusive) on influenza activity and vaccine uptake, we explore the optimal time to begin vaccinating older adults (≥65 years) in the U.S. to maximize prevention of influenza. We modelled the effect of changing the timing of vaccination by estimating the percentage change to the current disease burden and used this to calculate the estimated optimal week to begin vaccination in the U.S.
When we assumed a relatively slower waning protection rate (over 52 weeks), the estimated optimal time to begin vaccinating those aged ≥65 years varied between mid-August (week 34, 2012–2013) and mid-late October (week 43, 2011–2012) depending on the season, resulting in 0.44% and 5.11% of the current disease burden prevented respectively. Under faster waning (over 26 weeks), the estimated optimal week varied between early September (week 37, 2012–2013) and mid-November (week 47, 2011–2012), resulting in 3.69% and 11.97% of the current disease burden prevented respectively.
While it is difficult to determine the ideal time to start to vaccinate due to substantial variation in timing of individual seasons, we found that there are potentially substantial benefits to minimizing the time between vaccination and influenza activity in U.S. older adults. Modest delays in immunization were beneficial in the seasons we evaluated. If further evidence suggests fast waning, longer delays may be warrant as in these scenarios the timing of the current vaccination was often very suboptimal.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>30146403</pmid><doi>10.1016/j.vaccine.2018.08.007</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0264-410X |
ispartof | Vaccine, 2018-09, Vol.36 (39), p.5910-5915 |
issn | 0264-410X 1873-2518 |
language | eng |
recordid | cdi_proquest_miscellaneous_2094427414 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete; ProQuest Central UK/Ireland |
subjects | Adults Age Factors Aged Aged, 80 and over Elderly Female Health risks Humans Immunization Immunization Schedule Influenza Influenza Vaccines - administration & dosage Influenza, Human - epidemiology Influenza, Human - prevention & control Intraseason Laboratories Male Models, Theoretical Older people Population Seasons Timing United States - epidemiology Vaccination Vaccination - methods Vaccination Coverage Vaccines Waning |
title | Within-season influenza vaccine waning suggests potential net benefits to delayed vaccination in older adults in the United States |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T07%3A52%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Within-season%20influenza%20vaccine%20waning%20suggests%20potential%20net%20benefits%20to%20delayed%20vaccination%20in%20older%20adults%20in%20the%20United%20States&rft.jtitle=Vaccine&rft.au=Newall,%20A.T.&rft.date=2018-09-18&rft.volume=36&rft.issue=39&rft.spage=5910&rft.epage=5915&rft.pages=5910-5915&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2018.08.007&rft_dat=%3Cproquest_cross%3E2100343624%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2100343624&rft_id=info:pmid/30146403&rft_els_id=S0264410X18311149&rfr_iscdi=true |